Through the looking glass
Now that Novo Nordisk has released fourth quarter and full year results we can examine both Novo and Lilly who reported results last week. For us anyway it’s useless to not look at both companies at the same time. These two companies have been going at each other since we began writing Diabetic Investor and their battle over the years offers a glimpse into how much diabetes management has changed over the years.
Way back in the day Lilly was clearly the leader with Novo being a newbie to the US market. As we noted back then if Lilly . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.